1887
Rapid communications Open Access
Like 0
This item has no PDF Download

Abstract

Two prophylactic human papillomavirus (HPV) vaccines have been licensed in Europe: the quadrivalent vaccine, Gardasil® (Sanofi Pasteur MSD) and the bivalent vaccine, Cervarix® (GlaxoSmithKline Biologicals) [1,2]. Both vaccines are made from virus-like particles and are non-infectious [3]. Both vaccines protect against the high-risk HPV types 16 and 18, which cause an estimated 73% of cervical cancer cases in Europe. Gardasil also protects against HPV 6 and 11, which cause most cases of genital warts. Both vaccines have a good safety profile. They have been shown to prevent more than 90% of precancerous lesions associated with types 16 or 18 among HPV naïve women in clinical trials [4]. .

Loading

Article metrics loading...

/content/10.2807/ese.13.04.08022-en
2008-01-24
2017-12-16
http://instance.metastore.ingenta.com/content/10.2807/ese.13.04.08022-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/13/4/art08022-en.htm?itemId=/content/10.2807/ese.13.04.08022-en&mimeType=html&fmt=ahah
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error